title: A subclass of acylated anti-inflammatory mediators usurp Toll-like receptor 2 to inhibit neutrophil recruitment through peroxisome proliferator-activated receptor gamma.
abstract: Toll-like receptors are host sentinel receptors that signal the presence of infectious nonself and initiate protective immunity. One of the primary immune defense mechanisms is the recruitment of neutrophils from the bloodstream into the infected tissue. Although neutrophils are important in host defense, they can also be responsible for damaging pathologies associated with excessive inflammation. Here, we report that the di-acylated TLR2 ligand lipoteichoic acid can directly inhibit neutrophil recruitment in vivo. This discovery allowed us to test the concept that conventional proinflammatory TLR2 ligands can be made to act as inhibitors through specific structural modifications. Indeed, lipopeptide TLR2 ligands, when modified at their acyl chains to contain linoleate, lose their capacity to induce inflammation and yield ligands that can directly inhibit the in vivo neutrophil recruitment initiated by a wide range of proinflammatory stimuli. The inhibitory capacity of LTA and these modified ligands requires the expression of TLR2, but is independent of the TLR2 signaling adaptor, MyD88. Instead, this inhibitory effect requires functional activity of the fatty acid and nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ). Therefore, these data support a model in TLR2 biology where structural modifications of these ligands can profoundly influence host-microbial interactions. These inhibitory TLR2 ligands also have broader implications with respect to their potential use in various inflammatory disease settings.
authors.affiliation: Southern Alberta Cancer Research Institute, Department of Oncology and Biochemistry, Phoebe and Joan Snyder Institute of Inflammation, University of Calgary, Calgary, AB, Canada T2N 4N1.
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Long
authors.forename: Alexander C
authors.initials: AC
authors.lastname: Klimowicz
authors.forename: Heitor A
authors.initials: HA
authors.lastname: Paula-Neto
authors.forename: Brandie
authors.initials: B
authors.lastname: Millen
authors.forename: Donna-Marie
authors.initials: DM
authors.lastname: McCafferty
authors.forename: Paul
authors.initials: P
authors.lastname: Kubes
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Robbins
mesh_terms: D000215:Acylation; D000818:Animals; D018836:Inflammation Mediators / Q000378:metabolism*; D008024:Ligands; D008070:Lipopolysaccharides / Q000378:metabolism / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D047495:PPAR gamma / Q000502:physiology*; D013682:Teichoic Acids / Q000378:metabolism / Q000494:pharmacology*; D051195:Toll-Like Receptor 2 / Q000378:metabolism*
chemical_list: D018836:Inflammation Mediators; D008024:Ligands; D008070:Lipopolysaccharides; D047495:PPAR gamma; D013682:Teichoic Acids; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; C009900:lipoteichoic acid